Nomenclature: H1 receptor

Family: Histamine receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates. 

Contents

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 487 3p25 HRH1 histamine receptor H1 13-14,22,42,60
Mouse 7 488 6 E3 Hrh1 histamine receptor H1 32
Rat 7 486 4q42 Hrh1 histamine receptor H 1 20
Previous and Unofficial Names
Hisr
H1R
HH1R
Histamine receptor H1
histamine H1 receptor
histamine receptor H 1
Bphs
Hir
Database Links
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GPCRDB
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG Gene
OMIM
PharmGKB Gene
PhosphoSitePlus
Protein Ontology (PRO)
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene Hs.
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Histamine H1 receptor in complex with antagonist
PDB Id:  3RZE
Ligand:  doxepin
Resolution:  3.1Å
Species:  Human
References:  73
Natural/Endogenous Ligands
histamine
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
dimethylhistaprodifen Hs Full agonist 6.4 pKi 72
pKi 6.4 [72]
methylhistaprodifen Hs Full agonist 6.4 pKi 72
pKi 6.4 [72]
2-(3-iodophenyl)histamine Hs Full agonist 5.8 pKi 72
pKi 5.8 [72]
2-(3-bromophenyl)histamine Hs Full agonist 5.7 pKi 72
pKi 5.7 [72]
2-(3-chlorophenyl)histamine Hs Full agonist 5.7 pKi 72
pKi 5.7 [72]
histaprodifen Hs Full agonist 5.7 pKi 45
pKi 5.7 [45]
2-(2-thiazolyl)ethanamine Hs Partial agonist 5.34 pKi 72
pKi 5.34 [72]
histamine Hs Full agonist 4.7 – 5.9 pKi 6,60,68,72,80
pKi 4.7 – 5.9 [6,60,68,72,80]
UR-PG55B Hs Full agonist 5.2 pKi 80
pKi 5.2 [80]
UR-PG131A Hs Full agonist 4.7 pKi 80
pKi 4.7 [80]
UR-PG153 Hs Full agonist 4.7 pKi 80
pKi 4.7 [80]
UR-PG136 Hs Full agonist 4.5 pKi 80
pKi 4.5 [80]
UR-PG146 Hs Full agonist 4.4 pKi 80
pKi 4.4 [80]
2-pyridylethylamine Hs Full agonist 3.7 pKi 68
pKi 3.7 [68]
vilazodone Hs Agonist 6.5 pIC50 28
pIC50 6.5 (IC50 3.17x10-7 M) [28]
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[11C]doxepin Hs Antagonist 9.0 pKd 34
pKd 9.0 (Kd 1x10-9 M) [34]
[3H]pyrilamine Hs Inverse agonist 8.4 – 9.1 pKd 14,60,71-72
pKd 8.4 – 9.1 (Kd 7.9x10-10 – 4x10-9 M) [14,60,71-72]
tripelennamine Hs Antagonist 8.0 pKd 27
pKd 8.0 (Kd 1x10-8 M) [27]
clemastine Hs Antagonist 10.31 pKi 3
pKi 10.31 (Ki 4.9x10-11 M) [3]
cyproheptadine Hs Antagonist 10.2 pKi 60
pKi 10.2 [60]
asenapine Hs Antagonist 9.8 pKi 71
pKi 9.8 [71]
doxepin Hs Antagonist 9.5 – 10.0 pKi 6
pKi 9.5 – 10.0 [6]
promethazine Hs Antagonist 9.62 pKi 23
pKi 9.62 (Ki 2.4x10-10 M) [23]
clozapine Hs Antagonist 8.8 – 9.6 pKi 6,40,71
pKi 8.8 – 9.6 [6,40,71]
zotepine Hs Antagonist 9.2 pKi 71
pKi 9.2 [71]
desloratadine Hs Antagonist 9.01 pKi 43
pKi 9.01 (Ki 9.7x10-10 M) [43]
olanzapine Hs Antagonist 8.7 – 9.2 pKi 40,71
pKi 8.7 – 9.2 [40,71]
azelastine Hs Antagonist 8.9 pKi 67
pKi 8.9 (Ki 1.26x10-9 M) [67]
pyrilamine Hs Inverse agonist 8.7 – 9.0 pKi 6,68
pKi 8.7 – 9.0 [6,68]
triprolidine Hs Antagonist 8.5 – 9.0 pKi 6,60
pKi 8.5 – 9.0 [6,60]
(-)-trans-H2-PAT Hs Antagonist 8.6 – 8.8 pKi 6
pKi 8.6 – 8.8 [6]
hydroxyzine Hs Antagonist 8.7 pKi 24
pKi 8.7 (Ki 1.99x10-9 M) [24]
ketotifen Hs Antagonist 8.6 pKi 41
pKi 8.6 (Ki 2.5x10-9 M) [41]
astemizole Hs Antagonist 8.52 pKi 66
pKi 8.52 (Ki 3x10-9 M) [66]
(±)-trans-H2-PAT Hs Antagonist 8.4 – 8.6 pKi 6
pKi 8.4 – 8.6 [6]
(R)-cetirizine Hs Inverse agonist 8.5 pKi 68
pKi 8.5 [68]
(+)-chlorpheniramine Hs Antagonist 8.3 – 8.6 pKi 6,60
pKi 8.3 – 8.6 [6,60]
thiothixene Hs Antagonist 8.4 pKi 40
pKi 8.4 [40]
quetiapine Hs Antagonist 8.0 – 8.7 pKi 40,71
pKi 8.0 – 8.7 [40,71]
cyclizine Hs Antagonist 8.35 pKi 3
pKi 8.35 (Ki 4.44x10-9 M) [3]
cetirizine Hs Inverse agonist 8.2 pKi 60
pKi 8.2 [60]
chlorpromazine Hs Antagonist 8.2 pKi 40
pKi 8.2 [40]
loxapine Hs Antagonist 8.2 pKi 40
pKi 8.2 [40]
chlorpheniramine Hs Antagonist 8.15 pKi 67
pKi 8.15 (Ki 7x10-9 M) [67]
perphenazine Hs Antagonist 8.1 pKi 40
pKi 8.1 [40]
(±)-cis-H2-PAT Hs Antagonist 7.8 – 8.2 pKi 6
pKi 8.1 – 8.2 [6]
pKi 7.8 – 7.9 [6]
diphenhydramine Hs Antagonist 7.9 pKi 6
pKi 7.9 [6]
fluspirilene Hs Antagonist 7.9 pKi 71
pKi 7.9 [71]
thioridazine Hs Antagonist 7.7 pKi 40
pKi 7.7 [40]
risperidone Hs Antagonist 7.6 – 7.8 pKi 40,71
pKi 7.6 – 7.8 [40,71]
fluphenazine Hs Antagonist 7.7 pKi 40
pKi 7.7 [40]
ziprasidone Hs Antagonist 7.4 – 7.8 pKi 40,71
pKi 7.4 – 7.8 [40,71]
fexofenadine Hs Antagonist 7.57 pKi 2
pKi 7.57 (Ki 2.7x10-8 M) [2]
9-OH-risperidone Hs Antagonist 7.5 pKi 71
pKi 7.5 [71]
aripiprazole Hs Antagonist 7.5 pKi 40
pKi 7.5 [40]
(+)-trans-H2-PAT Hs Antagonist 7.4 – 7.5 pKi 6
pKi 7.4 – 7.5 [6]
loratadine Hs Antagonist 7.43 pKi 37
pKi 7.43 (Ki 3.7x10-8 M) [37]
terfenadine Hs Antagonist 7.4 pKi 2
pKi 7.4 (Ki 4x10-8 M) [2]
trifluoperazine Hs Antagonist 7.2 pKi 40
pKi 7.2 [40]
sertindole Hs Antagonist 6.9 pKi 40,71
pKi 6.9 [40,71]
(+)-cis-H2-PAT Hs Antagonist 6.9 pKi 6
pKi 6.9 [6]
(S)-cetirizine Hs Inverse agonist 6.7 pKi 68
pKi 6.7 [68]
BU-E 47 Hs Antagonist 6.6 pKi 72
pKi 6.6 [72]
(-)-chlorpheniramine Hs Antagonist 6.4 – 6.7 pKi 6
pKi 6.4 – 6.7 [6]
arpromidine Hs Antagonist 6.5 pKi 72,80
pKi 6.5 [72,80]
pimozide Hs Antagonist 6.2 pKi 40
pKi 6.2 [40]
haloperidol Hs Antagonist 5.7 – 6.1 pKi 40,71
pKi 5.7 – 6.1 [40,71]
ABT-239 Hs Inverse agonist 5.8 pKi 18
pKi 5.8 [18]
molindone Hs Antagonist 5.7 pKi 40
pKi 5.7 [40]
A-349821 Hs Inverse agonist 5.6 pKi 17
pKi 5.6 [17]
pipamperone Hs Antagonist 5.6 pKi 71
pKi 5.6 [71]
clobenpropit Hs Antagonist 5.6 pKi 19
pKi 5.6 [19]
A-317920 Hs Antagonist 5.4 pKi 17,19
pKi 5.4 [17,19]
impromidine Hs Antagonist 5.2 pKi 80
pKi 5.2 [80]
epinastine Hs Antagonist 7.6 pIC50 30
pIC50 7.6 (IC50 2.5x10-8 M) [30]
Description: Antagonism of 5 nM [3H]mepyramine binding in an intact cell assay using U373 MG astrocytoma cells.
tripelennamine Hs Antagonist 7.4 pIC50 27
pIC50 7.4 (IC50 3.98x10-8 M) [27]
Antagonist Comments
Astemizole is highly selective for the histamine H1 receptor over the H2 receptor.
Primary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Adenylate cyclase stimulation
Comments:  Stimulation of cAMP accumulation is via Gβγ subunits of Gq [51].
References:  51
Secondary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
References:  44
Tissue Distribution
Brain: cerebrum.
Heart: myocardium (ventricle > atrium).
Species:  Human
Technique:  Northern and Western blotting.
References:  55
Brain.
Species:  Human
Technique:  Positron emission tomography (PET).
References:  59
Cranial arteries.
Species:  Human
Technique:  RT-PCR.
References:  36
Myometrium.
Species:  Human
Technique:  Radioligand binding.
References:  25
Gastrointestinal tract.
Species:  Human
Technique:  qRT-PCR and immunohistochemistry.
References:  69
Uterine horns.
Species:  Mouse
Technique:  Radioligand binding.
References:  26
Mast cells.
Species:  Mouse
Technique:  RT-PCR.
References:  31
Sympathetic preganglionic neurons in the spinal cord.
Species:  Rat
Technique:  RT-PCR.
References:  78
Embryonic brain and spinal cord.
Species:  Rat
Technique:  in situ hybridization, RT-PCR and Northern blotting.
References:  39
Brain: cerebrum.
Heart: myocardium (atrium and ventricle).
Species:  Rat
Technique:  Northern and Western blotting.
References:  55
Cochlea.
Species:  Rat
Technique:  RT-PCR.
References:  4
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of cAMP levels in CHO cells transfected with the human H1 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of cAMP accumulation.
References:  51
Measurement of IP levels in COS-7 cells transfected with the human H1 receptor.
Species:  Human
Tissue:  COS-7 cells.
Response measured:  Stimulation of IP formation.
References:  13
Measurement of IP levels in CHO cells transfected with the human H1 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of IP formation.
References:  6
Measurement of AC activity in baculovirus-infected Sf9 insect cells expressing the human H1 receptor.
Species:  Human
Tissue:  Sf9 cells.
Response measured:  Stimulation of AC activity.
References:  80
Measurement of PLC activity and Ca2+ mobilisation in cultured ciliary muscle cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Cultured ciliary muscle cells.
Response measured:  Activation of PLC and mobilisation of both intracellular and extracellular Ca2+.
References:  49
Measurement of IP levels in cultured human endothelial cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Cultured umbilical vein endothelial cells.
Response measured:  Stimulation of IP formation.
References:  46
Measurement of mitogenesis in human astrocytoma U373 MG cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Astrocytoma U373 MG cells.
Response measured:  Cell proliferation via PKC and MAPK.
References:  29
Measurement of Ca2+ levels as well as ERK1/2 and PKC activity in human primary epithelial cells and the NCI-H292 cell line, both endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Primary epithelial cells and the NCI-H292 cell line.
Response measured:  Elevation of Ca2+ levels and activation of PKC and ERK1/2.
References:  54
Measurement of IP, DAG and Ca2+ levels in human HeLa carcinoma cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  HeLa carcinoma cells.
Response measured:  Formation of IP and DAG and a rise in Ca2+ levels.
References:  76
Physiological Functions
Hypernociception.
Species:  Rat
Tissue:  In vivo.
References:  48
Modulation of feeding behaviour.
Species:  Mouse
Tissue:  In vivo.
References:  52-53,61-62
Relaxation of smooth muscle (via an endothelial H1 receptor).
Species:  Human
Tissue:  Cranial arteries.
References:  36
Contraction of smooth muscle.
Species:  Human
Tissue:  Arterial rings.
References:  12
Modulation of adrenergic neurotransmission.
Species:  Rat
Tissue:  Vas deferens.
References:  77
Bronchoconstriction.
Species:  Human
Tissue:  In vivo.
References:  9-10,15,47,63,75
Inhibition of locomotor behaviour.
Species:  Rat
Tissue:  In vivo.
References:  1
Modulation of feeding behaviour.
Species:  Rat
Tissue:  In vivo.
References:  21
Endothelium-dependent vasodilation.
Species:  Rat
Tissue:  Mesenteric vascular beds.
References:  38
Role in the stimulation of skin blood flow during whole body heating.
Species:  Human
Tissue:  In vivo.
References:  79
Stimulation of the nitric oxide signalling system.
Species:  Rat
Tissue:  Submandibular gland.
References:  7
Increased vascular permeability.
Species:  Mouse
Tissue:  In vivo.
References:  5,64
Modulation of neuronal firing.
Species:  Rat
Tissue:  Dorsal raphe nucleus.
References:  8
Contraction of smooth muscle.
Species:  Human
Tissue:  Isolated uterine strips.
References:  50
Contraction of smooth muscle.
Species:  Rat
Tissue:  Isolated stomach fundus.
References:  16
Increase in substantia nigra pars reticulata (SNr) inhibitory projection neuron firing frequency (via cell depolarisation).
The balance between the effect of H1 and H2 receptors and the opposing effect of H3 receptors may contribute to movement control.
Species:  Mouse
Tissue:  Coronal midbrain slices.
References:  83
Depolarisation.
Species:  Rat
Tissue:  Sympathetic preganglionic neurons.
References:  78
Regulation of cytokine production.
Species:  Mouse
Tissue:  CD4+ and CD8+ T cells.
References:  74
Prostacyclin formation.
Species:  Human
Tissue:  Pulmonary artery.
References:  70
Physiological Consequences of Altering Gene Expression
H1 receptor knockout mice develop normally, but exhibit impaired locomotor activity and exploratory behavior.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  33,82
H1 receptor knockout mice subjected to social isolation after weaning exhibit similar levels of locomotor activity to socially reared H1 receptor knockout mice. This is in contrast to wild-type mice, where there is a significant decrease in locomotor activity in socially isolated WT mice compared with socially reared WT mice. It is suggested that blockade of H1 receptors by atypical antipsychotics attenuates social isolation-induced behavioral changes.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  11
H1 receptor knockout mice exhibit decreased exploratory activity, reduced levels of anxiety and aggression, a decrease in nociceptive response and an increased 5-HT turnover rate in the cerebral cortex and hippocampus.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  81
H1 receptor knockout mice exhibit a significant decrease in nociception compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  57
H1 knockout mice exhibit enhancement of morphine-induced antinociception.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  56
H1 receptor knockout mice do not exhibit an increase in respiratory frequency upon elevation of body temperature, as observed in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  35
H1 receptor knockout mice exhibit a reduction in the effect of neurotensin on the supression of food intake.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  65
H1 receptor knockout mice do not exhibit an increase in vascular permeability of the conjunctiva, as observed in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  64
CD4+ T cells from H1 receptor knockout mice exhibit a decrease in the release of Il-2 and Il-10, and an increase in the release of IL-4. CD8+ T cells from H1 receptor knockout mice also exhibit a decrease in the release of Il-2 and Il-10, as well as an increase in the release of IFN-γ.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  74
H1 receptor knockout mice exhibit enhanced antinociception by administration of orexin-A, compared to wild-type mice following administration of orexin-A.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  58
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0004924 abnormal behavior PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0001502 abnormal circadian rhythm PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0005093 decreased B cell proliferation PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0001262 decreased body weight PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0002727 decreased circulating insulin level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0003910 decreased eating behavior PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0001417 decreased exploration in new environment PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0008498 decreased IgG3 level PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0001806 decreased IgM level PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0001876 decreased inflammatory response PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0008567 decreased interferon-gamma secretion PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0008567 decreased interferon-gamma secretion PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0008673 decreased interleukin-13 secretion PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0008688 decreased interleukin-2 secretion PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0008703 decreased interleukin-5 secretion PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0005018 decreased T cell number PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0005095 decreased T cell proliferation PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0010025 decreased total body fat amount PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0002757 decreased vertical activity PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0001260 increased body weight PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0000005 increased brown adipose tissue amount PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0001554 increased circulating free fatty acid level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0005669 increased circulating leptin level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0003909 increased eating behavior PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0006094 increased fat cell size PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0002493 increased IgG level PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0002494 increased IgM level PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0008699 increased interleukin-4 secretion PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0009355 increased liver triglyceride level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0005317 increased triglyceride level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0000008 increased white adipose tissue amount PMID: 15331534 
Available Assays
DiscoveRx PathHunter® CHO-K1 HRH1 β-Arrestin Cell Line (Cat no. 93-0503C2)
PathHunter® eXpress HRH1 CHO-K1 β-Arrestin GPCR Assay (Cat no. 93-0503E2CP2M)
more info

REFERENCES

1. Alvarez EO, Banzán AM. (1986) Histamine in dorsal and ventral hippocampus. II. Effects of H1 and H2 histamine antagonists on exploratory behavior in male rats. Physiol Behav37: 39-45. [PMID:3016772]

2. Aslanian R, Piwinski JJ, Zhu X, Priestley T, Sorota S, Du XY, Zhang XS, McLeod RL, West RE, Williams SM et al.. (2009) Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg. Med. Chem. Lett.19 (17): 5043-7. [PMID:19660947]

3. Auerbach SS, DrugMatrix® and ToxFX® Coordinator National Toxicology Program. National Toxicoligy Program: Dept of Health and Human Services. Accessed on 02/05/2014. Modified on 02/05/2014. DrugMatrix, https://ntp.niehs.nih.gov/drugmatrix/index.html

4. Azuma H, Sawada S, Takeuchi S, Higashiyama K, Kakigi A, Takeda T. (2003) Expression of mRNA encoding the H1, H2, and H3 histamine receptors in the rat cochlea. Neuroreport14: 423-425. [PMID:12634496]

5. Bhargava KP, Nath R, Palit G. (1977) Nature of histamine receptors concerned in capillary permeability. Br J Pharmacol59: 349-351. [PMID:837022]

6. Booth RG, Moniri NH, Bakker RA, Choksi NY, Nix WB, Timmerman H, Leurs R. (2002) A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. J Pharmacol Exp Ther302: 328-336. [PMID:12065734]

7. Borda E, Stranieri G, Sterin-Borda L. (2002) H(1)-Receptor activation triggers the endogenous nitric oxide signalling system in the rat submandibular gland. Mediators Inflamm11: 337-343. [PMID:12581497]

8. Bárbara A, Aceves J, Arias-Montaño JA. (2002) Histamine H1 receptors in rat dorsal raphe nucleus: pharmacological characterisation and linking to increased neuronal activity. Brain Res954: 247-255. [PMID:12414108]

9. Casterline CL, Evans R. (1977) Further studies on the mechanism of human histamine-induced asthma: the effect of an aerosolized H1 receptor antagonist (diphenhydramine). J Allergy Clin Immunol59: 420-424. [PMID:16944]

10. Crimi N, Polosa R, Magrì S, Prosperini G, Paolino G, Mastruzzo C, Mistretta A. (1996) Inhaled lysine acetylsalicylate (L-ASA) attenuates histamine-induced bronchoconstriction in asthma. Allergy51: 157-163. [PMID:8781669]

11. Dai H, Okuda T, Sakurai E, Kuramasu A, Kato M, Jia F, Xu AJ, Iinuma K, Sato I, Yanai K. (2005) Blockage of histamine H1 receptor attenuates social isolation-induced disruption of prepulse inhibition: a study in H1 receptor gene knockout mice. Psychopharmacology (Berl)183: 285-293. [PMID:16237577]

12. Daneshmand MA, Keller RS, Canver MC, Canver AC, Canver CC. (2004) Histamine H1 and H2 receptor-mediated vasoreactivity of human internal thoracic and radial arteries. Surgery136: 458-463. [PMID:15300215]

13. De Backer MD, Gommeren W, Moereels H, Nobels G, Van Gompel P, Leysen JE, Luyten WH. (1993) Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor. Biochem Biophys Res Commun197: 1601-1608. [PMID:8280179]

14. De Backer MD, Loonen I, Verhasselt P, Neefs JM, Luyten WH. (1998) Structure of the human histamine H1 receptor gene. Biochem J335: 663-670. [PMID:9794809]

15. Eiser NM, Mills J, Snashall PD, Guz A. (1981) The role of histamine receptors in asthma. Clin Sci (Lond)60: 363-370. [PMID:7249528]

16. Ercan ZS, Türker RK. (1977) Histamine receptors in the isolated rat stomach fundus and rabbit aortic strips. Pharmacology15: 118-126. [PMID:847009]

17. Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA. (2004) Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem Pharmacol68: 933-945. [PMID:15294456]

18. Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA. (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J Pharmacol Exp Ther313: 165-175. [PMID:15608078]

19. Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, Williams M, Hancock AA. (2003) Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J Pharmacol Exp Ther305: 887-896. [PMID:12606603]

20. Fujimoto K, Horio Y, Sugama K, Ito S, Liu YQ, Fukui H. (1993) Genomic cloning of the rat histamine H1 receptor. Biochem Biophys Res Commun190: 294-301. [PMID:7678492]

21. Fukagawa K, Sakata T, Shiraishi T, Yoshimatsu H, Fujimoto K, Ookuma K, Wada H. (1989) Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. Am J Physiol256: R605-R611. [PMID:2564258]

22. Fukui H, Fujimoto K, Mizuguchi H, Sakamoto K, Horio Y, Takai S, Yamada K, Ito S. (1994) Molecular cloning of the human H1-receptor gene. Biochem. Biophys. Res. Commun.201: 894-901. [PMID:8003029]

23. Ghoneim OM, Legere JA, Golbraikh A, Tropsha A, Booth RG. (2006) Novel ligands for the human histamine H1 receptor: synthesis, pharmacology, and comparative molecular field analysis studies of 2-dimethylamino-5-(6)-phenyl-1,2,3,4-tetrahydronaphthalenes. Bioorg. Med. Chem.14 (19): 6640-58. [PMID:16782354]

24. Gillard M, Van Der Perren C, Moguilevsky N, Massingham R, Chatelain P. (2002) Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol. Pharmacol.61 (2): 391-9. [PMID:11809864]

25. Gonzalez R, Echeverria E, Reinicke K, Rudolph MI. (1994) Increased affinity of histamine H1 binding to membranes of human myometrium at the end of pregnancy. Gen Pharmacol25: 1607-1610. [PMID:7721035]

26. Gonzalez R, Reinicke K, Rudolph GM. (1993) Histamine H1 receptor binding sites in mouse uterine horns. Gen Pharmacol24: 29-33. [PMID:8482504]

27. Govoni M, Bakker RA, van de Wetering I, Smit MJ, Menge WM, Timmerman H, Elz S, Schunack W, Leurs R. (2003) Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists. J. Med. Chem.46 (26): 5812-24. [PMID:14667234]

28. Heinrich T, Böttcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, Van Amsterdam C. (2004) Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J. Med. Chem.47 (19): 4684-92. [PMID:15341484]

29. Hernández-Angeles A, Soria-Jasso LE, Ortega A, Arias-Montaño JA. (2001) Histamine H1 receptor activation stimulates mitogenesis in human astrocytoma U373 MG cells. J Neurooncol55: 81-89. [PMID:11817705]

30. Hishinuma S, Sato Y, Kobayashi Y, Komazaki H, Saito M. (2008) Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J. Pharmacol. Sci.107 (1): 66-79. [PMID:18446005]

31. Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP. (2003) Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther305: 1212-1221. [PMID:12626656]

32. Inoue I, Taniuchi I, Kitamura D, Jenkins NA, Gilbert DJ, Copeland NG, Watanabe T. (1996) Characteristics of the mouse genomic histamine H1 receptor gene. Genomics36: 178-181. [PMID:8812432]

33. Inoue I, Yanai K, Kitamura D, Taniuchi I, Kobayashi T, Niimura K, Watanabe T, Watanabe T. (1996) Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci U S A93: 13316-13320. [PMID:8917588]

34. Ishiwata K, Kawamura K, Wang WF, Tsukada H, Harada N, Mochizuki H, Kimura Y, Ishii K, Iwata R, Yanai K. (2004) Evaluation of in vivo selective binding of [11C]doxepin to histamine H1 receptors in five animal species. Nucl. Med. Biol.31 (4): 493-502. [PMID:15093820]

35. Izumizaki M, Iwase M, Kimura H, Yanai K, Watanabe T, Homma I. (2000) Lack of temperature-induced polypnea in histamine H1 receptor-deficient mice. Neurosci Lett284: 139-142. [PMID:10773418]

36. Jansen-Olesen I, Ottosson A, Cantera L, Strunk S, Lassen LH, Olesen J, Mortensen A, Engel U, Edvinsson L. (1997) Role of endothelium and nitric oxide in histamine-induced responses in human cranial arteries and detection of mRNA encoding H1- and H2-receptors by RT-PCR. Br J Pharmacol121: 41-48. [PMID:9146885]

37. Janssens F, Leenaerts J, Diels G, De Boeck B, Megens A, Langlois X, van Rossem K, Beetens J, Borgers M. (2005) Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines. J. Med. Chem.48 (6): 2154-66. [PMID:15771458]

38. Jin H, Koyama T, Hatanaka Y, Akiyama S, Takayama F, Kawasaki H. (2006) Histamine-induced vasodilation and vasoconstriction in the mesenteric resistance artery of the rat. Eur J Pharmacol529: 136-144. [PMID:16337938]

39. Kinnunen A, Lintunen M, Karlstedt K, Fukui H, Panula P. (1998) In situ detection of H1-receptor mRNA and absence of apoptosis in the transient histamine system of the embryonic rat brain. J Comp Neurol394: 127-137. [PMID:9550146]

40. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology28: 519-526. [PMID:12629531]

41. Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y. (2011) Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines. Bioorg. Med. Chem.19 (9): 3005-21. [PMID:21470866]

42. Le Coniat M, Traiffort E, Ruat M, Arrang JM, Berger R. (1994) Chromosomal localisation of the human histamine H1-receptor gene. Hum. Genet.94: 186-188. [PMID:8045566]

43. Lewis TA, Young MA, Arrington MP, Bayless L, Cai X, Collart P, Eckman JB, Ellis JL, Ene DG, Libertine L et al.. (2004) Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg. Med. Chem. Lett.14 (22): 5591-4. [PMID:15482930]

44. Li H, Choe NH, Wright DT, Adler KB. (1995) Histamine provokes turnover of inositol phospholipids in guinea pig and human airway epithelial cells via an H1-receptor/G protein-dependent mechanism. Am J Respir Cell Mol Biol12: 416-424. [PMID:7695921]

45. Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, Leurs R. (2005) Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther314: 1310-1321. [PMID:15947036]

46. Lo WW, Fan TP. (1987) Histamine stimulates inositol phosphate accumulation via the H1-receptor in cultured human endothelial cells. Biochem Biophys Res Commun148: 47-53. [PMID:3675593]

47. Maconochie JG, Woodings EP, Richards DA. (1979) Effects of H1- and H2-receptor blocking agents on histamine-induced bronchoconstriction in non-asthmatic subjects. Br J Clin Pharmacol7: 231-236. [PMID:34415]

48. Malmberg-Aiello P, Lamberti C, Ipponi A, Bartolini A, Schunack W. (1998) Evidence for hypernociception induction following histamine H1 receptor activation in rodents. Life Sci63: 463-476. [PMID:9718070]

49. Markwardt KL, Magnino PE, Pang IH. (1996) Effect of histamine on phosphoinositide turnover and intracellular calcium in human ciliary muscle cells. Exp Eye Res62: 511-520. [PMID:8759520]

50. Martínez-Mir MI, Estañ L, Morales-Olivas FJ, Rubio E. (1992) Effect of histamine and histamine analogues on human isolated myometrial strips. Br J Pharmacol107: 528-531. [PMID:1358393]

51. Maruko T, Nakahara T, Sakamoto K, Saito M, Sugimoto N, Takuwa Y, Ishii K. (2005) Involvement of the betagamma subunits of G proteins in the cAMP response induced by stimulation of the histamine H1 receptor. Naunyn Schmiedebergs Arch Pharmacol372: 153-159. [PMID:16189696]

52. Masaki T, Chiba S, Yasuda T, Noguchi H, Kakuma T, Watanabe T, Sakata T, Yoshimatsu H. (2004) Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes53: 2250-2260. [PMID:15331534]

53. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. (2001) Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes50: 385-391. [PMID:11272151]

54. Matsubara M, Ohmori K, Hasegawa K. (2006) Histamine H1 receptor-stimulated interleukin 8 and granulocyte macrophage colony-stimulating factor production by bronchial epithelial cells requires extracellular signal-regulated kinase signaling via protein kinase C. Int Arch Allergy Immunol139: 279-293. [PMID:16491014]

55. Matsuda N, Jesmin S, Takahashi Y, Hatta E, Kobayashi M, Matsuyama K, Kawakami N, Sakuma I, Gando S, Fukui H, Hattori Y, Levi R. (2004) Histamine H1 and H2 receptor gene and protein levels are differentially expressed in the hearts of rodents and humans. J Pharmacol Exp Ther309: 786-795. [PMID:14752062]

56. Mobarakeh JI, Sakurada S, Hayashi T, Orito T, Okuyama K, Sakurada T, Kuramasu A, Watanabe T, Watanabe T, Yanai K. (2002) Enhanced antinociception by intrathecally-administered morphine in histamine H1 receptor gene knockout mice. Neuropharmacology42: 1079-1088. [PMID:12128009]

57. Mobarakeh JI, Sakurada S, Katsuyama S, Kutsuwa M, Kuramasu A, Lin ZY, Watanabe T, Hashimoto Y, Yanai K. (2000) Role of histamine H(1) receptor in pain perception: a study of the receptor gene knockout mice. Eur J Pharmacol391: 81-89. [PMID:10720638]

58. Mobarakeh JI, Takahashi K, Sakurada S, Nishino S, Watanabe H, Kato M, Naghdi N, Yanai K. (2005) Enhanced antinociception by intracerebroventricularly administered orexin A in histamine H1 or H2 receptor gene knockout mice. Pain118: 254-262. [PMID:16202530]

59. Mochizuki H, Kimura Y, Ishii K, Oda K, Sasaki T, Tashiro M, Yanai K, Ishiwata K. (2004) Quantitative measurement of histamine H(1) receptors in human brains by PET and [11C]doxepin. Nucl Med Biol31: 165-171. [PMID:15013481]

60. Moguilevsky N, Varsalona F, Noyer M, Gillard M, Guillaume JP, Garcia L, Szpirer C, Szpirer J, Bollen A. (1994) Stable expression of human H1-histamine-receptor cDNA in Chinese hamster ovary cells. Pharmacological characterisation of the protein, tissue distribution of messenger RNA and chromosomal localisation of the gene. Eur J Biochem224: 489-495. [PMID:7925364]

61. Mollet A, Lutz TA, Meier S, Riediger T, Rushing PA, Scharrer E. (2001) Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am J Physiol Regul Integr Comp Physiol281: R1442-R1448. [PMID:11641114]

62. Morimoto T, Yamamoto Y, Mobarakeh JI, Yanai K, Watanabe T, Watanabe T, Yamatodani A. (1999) Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol Behav67: 679-683. [PMID:10604837]

63. Myou S, Fujimura M, Nishi K, Ohka T, Matsuda T. (1995) Inhibitory effect of terfenadine, a selective H1 histamine antagonist, on alcoholic beverage-induced bronchoconstriction in asthmatic patients. Eur Respir J8: 619-623. [PMID:7545133]

64. Nakahara H, Izushi K, Sugimoto Y, Watanabe T, Kamei C. (2000) Vascular permeability in allergic conjunctivitis in mice lacking histamine H1 receptors. Eur J Pharmacol409: 313-317. [PMID:11108826]

65. Ohinata K, Shimano T, Yamauchi R, Sakurada S, Yanai K, Yoshikawa M. (2004) The anorectic effect of neurotensin is mediated via a histamine H1 receptor in mice. Peptides25: 2135-2138. [PMID:15572202]

66. Pearlstein R, Vaz R, Rampe D. (2003) Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J. Med. Chem.46 (11): 2017-22. [PMID:12747773]

67. Procopiou PA, Browning C, Buckley JM, Clark KL, Fechner L, Gore PM, Hancock AP, Hodgson ST, Holmes DS, Kranz M et al.. (2011) The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis. J. Med. Chem.54 (7): 2183-95. [PMID:21381763]

68. Ratnala VR, Swarts HG, VanOostrum J, Leurs R, DeGroot HJ, Bakker RA, DeGrip WJ. (2004) Large-scale overproduction, functional purification and ligand affinities of the His-tagged human histamine H1 receptor. Eur J Biochem271: 2636-2646. [PMID:15206929]

69. Sander LE, Lorentz A, Sellge G, Coëffier M, Neipp M, Veres T, Frieling T, Meier PN, Manns MP, Bischoff SC. (2006) Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut55: 498-504. [PMID:16299042]

70. Schellenberg RR, Duff MJ, Foster A, Paddon HB. (1986) Histamine releases PGI2 from human pulmonary artery. Prostaglandins32: 201-209. [PMID:3541061]

71. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl)124: 57-73. [PMID:8935801]

72. Seifert R, Wenzel-Seifert K, Burckstummer T, Pertz HH, Schunack W, Dove S, Buschauer A, Elz S. (2003) Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther305: 1104-1115. [PMID:12626648]

73. Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, Abagyan R, Cherezov V, Liu W, Han GW et al.. (2011) Structure of the human histamine H1 receptor complex with doxepin. Nature475 (7354): 65-70. [PMID:21697825]

74. Sonobe Y, Nakane H, Watanabe T, Nakano K. (2004) Regulation of Con A-dependent cytokine production from CD4+ and CD8+ T lymphocytes by autosecretion of histamine. Inflamm Res53: 87-92. [PMID:15021962]

75. Thomson NC, Kerr JW. (1980) Effect of inhaled H1 and H2 receptor antagonist in normal and asthmatic subjects. Thorax35: 428-434. [PMID:6449094]

76. Tilly BC, Tertoolen LG, Lambrechts AC, Remorie R, de Laat SW, Moolenaar WH. (1990) Histamine-H1-receptor-mediated phosphoinositide hydrolysis, Ca2+ signalling and membrane-potential oscillations in human HeLa carcinoma cells. Biochem J266: 235-243. [PMID:2155607]

77. Todorov S, Zamfirova R. (1986) The role of H1- and H2-receptors in the modulatory effects of histaminergic agents on adrenergic neurotransmission in rat vas deferens. Methods Find Exp Clin Pharmacol8: 705-709. [PMID:3027468]

78. Whyment AD, Blanks AM, Lee K, Renaud LP, Spanswick D. (2006) Histamine excites neonatal rat sympathetic preganglionic neurons in vitro via activation of H1 receptors. J Neurophysiol95: 2492-2500. [PMID:16354729]

79. Wong BJ, Wilkins BW, Minson CT. (2004) H1 but not H2 histamine receptor activation contributes to the rise in skin blood flow during whole body heating in humans. J Physiol560: 941-948. [PMID:15375193]

80. Xie SX, Ghorai P, Ye QZ, Buschauer A, Seifert R. (2006) Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther317: 139-146. [PMID:16394198]

81. Yanai K, Son LZ, Endou M, Sakurai E, Nakagawasai O, Tadano T, Kisara K, Inoue I, Watanabe T, Watanabe T. (1998) Behavioural characterization and amounts of brain monoamines and their metabolites in mice lacking histamine H1 receptors. Neuroscience87: 479-487. [PMID:9740406]

82. Yanai K, Son LZ, Endou M, Sakurai E, Watanabe T. (1998) Targeting disruption of histamine H1 receptors in mice: behavioral and neurochemical characterization. Life Sci62: 1607-1610. [PMID:9585144]

83. Zhou FW, Xu JJ, Zhao Y, Ledoux MS, Zhou FM. (2006) Opposite Functions of Histamine H1 and H2 Receptors and H3 Receptor in Substantia Nigra Pars Reticulata. J Neurophysiol, : -. [PMID:16738217]

To cite this database page, please use the following:

Paul Chazot, Hiroyuki Fukui, C. Robin Ganellin, Helmut L. Haas, Stephen J. Hill, Rebecca Hills, Roberto Levi, Walter Schunack, Jean-Charles Schwartz, Nigel P. Shankley, Henk Timmerman, J. Michael Young.
Histamine receptors: H1 receptor. Last modified on 19/05/2014. Accessed on 01/10/2014. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=262.

Contact us | Print | Back to top | Help
Copyright © 2014 IUPHAR